Literature DB >> 17785465

Conditional deletion of gremlin causes a transient increase in bone formation and bone mass.

Elisabetta Gazzerro1, Anna Smerdel-Ramoya, Stefano Zanotti, Lisa Stadmeyer, Deena Durant, Aris N Economides, Ernesto Canalis.   

Abstract

Gremlin is a glycoprotein that binds bone morphogenetic proteins (BMPs) 2, 4, and 7, antagonizing their actions. Gremlin opposes BMP effects on osteoblastic differentiation and function in vitro and in vivo, and its overexpression causes osteopenia. To define the function of gremlin in the skeleton, we generated gremlin 1 (grem1) conditional null mice by mating mice where grem1 was flanked by lox(P) sequences with mice expressing the Cre recombinase under the control of the osteocalcin promoter. grem1 null male mice displayed increased trabecular bone volume due to enhanced osteoblastic activity, because mineral apposition and bone formation rates were increased. Osteoblast number and bone resorption were not altered. Marrow stromal cells from grem1 conditional null mice expressed higher levels of alkaline phosphatase activity. Gremlin down-regulation by RNA interference in ST-2 stromal and MC3T3 osteoblastic cells increased the BMP-2 stimulatory effect on alkaline phosphatase activity, on Smad 1/5/8 phosphorylation, and on the transactivation of the BMP/Smad reporter construct 12xSBE-Oc-pGL3. Gremlin down-regulation also enhanced osteocalcin and Runx-2 expression, Wnt 3a signaling, and activity in ST-2 cells. In conclusion, deletion of grem1 in the bone microenvironment results in sensitization of BMP signaling and activity and enhanced bone formation in vivo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17785465     DOI: 10.1074/jbc.M701317200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  54 in total

Review 1.  Update in new anabolic therapies for osteoporosis.

Authors:  Ernesto Canalis
Journal:  J Clin Endocrinol Metab       Date:  2010-04       Impact factor: 5.958

Review 2.  Technologies for controlled, local delivery of siRNA.

Authors:  Samantha M Sarett; Christopher E Nelson; Craig L Duvall
Journal:  J Control Release       Date:  2015-11-28       Impact factor: 9.776

Review 3.  Quantitative trait loci, genes, and polymorphisms that regulate bone mineral density in mouse.

Authors:  Qing Xiong; Yan Jiao; Karen A Hasty; S Terry Canale; John M Stuart; Wesley G Beamer; Hong-Wen Deng; David Baylink; Weikuan Gu
Journal:  Genomics       Date:  2009-01-14       Impact factor: 5.736

Review 4.  Antisense makes sense in engineered regenerative medicine.

Authors:  Yongchang Yao; Chunming Wang; Rohan R Varshney; Dong-An Wang
Journal:  Pharm Res       Date:  2008-11-18       Impact factor: 4.200

5.  Loss of gremlin delays primordial follicle assembly but does not affect female fertility in mice.

Authors:  Michelle Myers; Swamy K Tripurani; Brooke Middlebrook; Aris N Economides; Ernesto Canalis; Stephanie A Pangas
Journal:  Biol Reprod       Date:  2011-08-10       Impact factor: 4.285

6.  Nephroblastoma overexpressed (Nov) induces gremlin in ST-2 stromal cell lines by post-transcriptional mechanisms.

Authors:  Anna Smerdel-Ramoya; Stefano Zanotti; Ernesto Canalis
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

Review 7.  Bone morphogenetic proteins and their antagonists: current and emerging clinical uses.

Authors:  Imran H A Ali; Derek P Brazil
Journal:  Br J Pharmacol       Date:  2014-08       Impact factor: 8.739

Review 8.  TGF-β Family Signaling in Mesenchymal Differentiation.

Authors:  Ingo Grafe; Stefanie Alexander; Jonathan R Peterson; Taylor Nicholas Snider; Benjamin Levi; Brendan Lee; Yuji Mishina
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

Review 9.  Agonists and Antagonists of TGF-β Family Ligands.

Authors:  Chenbei Chang
Journal:  Cold Spring Harb Perspect Biol       Date:  2016-08-01       Impact factor: 10.005

Review 10.  Growth factor control of bone mass.

Authors:  Ernesto Canalis
Journal:  J Cell Biochem       Date:  2009-11-01       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.